Veterinary Molecular Diagnostics

Global Veterinary Molecular Diagnostics Market to Reach US$984.2 Million by 2030

The global market for Veterinary Molecular Diagnostics estimated at US$596.5 Million in the year 2023, is expected to reach US$984.2 Million by 2030, growing at a CAGR of 7.4% over the analysis period 2023-2030. Instruments & Software, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$342.8 Million by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$156.7 Million While China is Forecast to Grow at 11.0% CAGR

The Veterinary Molecular Diagnostics market in the U.S. is estimated at US$156.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$238.9 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Veterinary Molecular Diagnostics Market - Key Trends & Growth Drivers Explored

Why Are Veterinary Molecular Diagnostics Revolutionizing Animal Health Management?

Veterinary molecular diagnostics have emerged as a transformative tool in animal healthcare, enabling precise and rapid detection of diseases at the molecular level. But what makes these diagnostic methods so essential in modern veterinary practices? Veterinary molecular diagnostics are advanced testing techniques that identify genetic material, such as DNA and RNA, from pathogens, tumors, or genetic disorders in animals. These tests include polymerase chain reaction (PCR), real-time PCR, next-generation sequencing (NGS), and microarrays, among others, which can detect and quantify pathogens, genetic mutations, or biomarkers with high sensitivity and specificity. By targeting the genetic basis of diseases, these diagnostics allow veterinarians to diagnose conditions early, often before clinical symptoms appear, providing a crucial window for timely intervention and treatment.

The demand for veterinary molecular diagnostics is driven by the growing prevalence of zoonotic diseases, the rising incidence of chronic and infectious conditions in animals, and the increasing focus on preventive healthcare. These diagnostics are widely used in the detection of infectious diseases such as parvovirus, feline leukemia, and bovine respiratory disease, as well as for genetic screening in breeding programs to prevent the transmission of hereditary disorders. Molecular diagnostics have also become indispensable in the field of oncology, where they are used to identify specific mutations and biomarkers that can guide targeted therapies for cancer treatment. Furthermore, the ability to differentiate between closely related pathogens and detect multiple pathogens in a single test has made molecular diagnostics a preferred choice in complex cases where traditional testing methods may fall short. As pet owners, livestock managers, and veterinarians seek more accurate and reliable diagnostic solutions, veterinary molecular diagnostics are poised to play an increasingly central role in animal health management.

How Are Technological Advancements Elevating the Performance of Veterinary Molecular Diagnostics?

The veterinary molecular diagnostics market has experienced significant technological advancements that have enhanced the precision, speed, and accessibility of these diagnostic tools. But what are the key innovations driving these developments? One of the most impactful advancements is the evolution of real-time PCR (qPCR) technology. qPCR has become a gold standard in veterinary diagnostics due to its ability to amplify and quantify DNA or RNA sequences in real-time, providing rapid and highly sensitive results. Modern qPCR systems are equipped with multiplexing capabilities, allowing the simultaneous detection of multiple pathogens or genetic markers in a single sample. This innovation has significantly reduced turnaround times and the need for multiple tests, enabling veterinarians to make quicker and more informed decisions. Additionally, the integration of automated sample preparation systems has streamlined the workflow, reducing the potential for human error and increasing the consistency and reliability of test results.

Another critical innovation is the advent of next-generation sequencing (NGS) technology, which has revolutionized the field of veterinary genomics. NGS allows for comprehensive genetic analysis by sequencing entire genomes or targeted regions of interest, providing insights into complex genetic traits, disease mechanisms, and microbial communities. This technology is being increasingly used in research and clinical settings for applications such as pathogen discovery, antimicrobial resistance monitoring, and cancer genotyping. The development of portable and point-of-care molecular diagnostic devices has further expanded the reach of these technologies, enabling veterinarians to conduct testing on-site, whether in clinics, farms, or field settings. These devices are designed to be user-friendly, requiring minimal training and infrastructure, making advanced molecular diagnostics accessible even in remote or resource-limited environments. Furthermore, advancements in bioinformatics and data analytics have enhanced the interpretation of molecular diagnostic results, allowing for more accurate and actionable insights. These technological innovations have collectively elevated the performance and utility of veterinary molecular diagnostics, making them indispensable tools for modern veterinary medicine.

What Market Trends Are Driving the Adoption of Veterinary Molecular Diagnostics Across Animal Healthcare?

Several emerging market trends are shaping the adoption of veterinary molecular diagnostics across the animal healthcare sector, reflecting the evolving needs and expectations of veterinarians, researchers, and pet owners. One of the most prominent trends is the increasing focus on preventive care and early disease detection. As pet owners and livestock managers become more aware of the benefits of early diagnosis, there is a growing demand for diagnostic tools that can detect diseases at the subclinical stage, before they become symptomatic or spread to other animals. Veterinary molecular diagnostics, with their high sensitivity and specificity, are well-suited for this purpose, allowing for the early identification of infectious agents, genetic disorders, and cancerous cells. This trend is particularly strong in the companion animal sector, where regular health screenings and wellness programs are becoming more common. The ability to detect genetic predispositions and infectious diseases early enables veterinarians to implement targeted preventive measures and develop personalized treatment plans, improving health outcomes and reducing the long-term costs of care.

Another key trend driving the adoption of veterinary molecular diagnostics is the rising prevalence of zoonotic diseases and the need for effective disease surveillance. Zoonotic diseases, which are transmitted between animals and humans, pose a significant public health risk, making early and accurate diagnosis essential for controlling outbreaks and preventing cross-species transmission. The COVID-19 pandemic has underscored the importance of robust disease surveillance systems, leading to increased investment in diagnostic infrastructure for both companion animals and livestock. Veterinary molecular diagnostics are playing a critical role in this effort by providing tools that can detect zoonotic pathogens rapidly and accurately, supporting efforts to track and control disease spread. This trend is particularly evident in regions with large livestock populations, such as North America and Europe, where molecular diagnostics are used to monitor diseases like avian influenza, bovine tuberculosis, and African swine fever. The growing demand for comprehensive disease surveillance and biosecurity measures is expected to continue driving the adoption of molecular diagnostics in both the public and private sectors, reinforcing their role as key instruments in animal health management.

What Factors Are Driving the Growth of the Global Veterinary Molecular Diagnostics Market?

The growth in the global veterinary molecular diagnostics market is driven by several factors, including advancements in diagnostic technology, increasing investment in animal healthcare, and rising awareness of zoonotic diseases. One of the primary growth drivers is the expanding pet population and the humanization of pets, where owners treat their animals as family members and are willing to invest in advanced healthcare services. This has led to a surge in demand for diagnostic tests that provide quick and accurate results, enabling early diagnosis and effective treatment. The development of user-friendly and automated molecular diagnostic platforms has made it easier for veterinary clinics and hospitals to incorporate these tests into their routine diagnostic offerings, further boosting market growth. The increasing use of molecular diagnostics in livestock management is another key growth driver, as farmers and producers seek to improve herd health, productivity, and disease control.

Another significant growth driver is the rising incidence of infectious diseases and the growing need for effective disease management and control. Outbreaks of diseases like avian influenza, African swine fever, and canine parvovirus have highlighted the importance of rapid and accurate diagnostics for preventing disease spread and minimizing economic losses. Veterinary molecular diagnostics provide a reliable solution for detecting and differentiating pathogens, enabling veterinarians to implement timely and targeted interventions. The growing focus on antimicrobial resistance (AMR) is also contributing to market growth, as molecular diagnostics can identify resistance genes and guide the appropriate use of antibiotics, reducing the risk of resistance development. Furthermore, the expansion of veterinary diagnostic laboratories and research institutions, particularly in emerging markets such as Asia-Pacific and Latin America, is creating new opportunities for market growth. As these regions invest in modernizing their veterinary infrastructure and improving access to advanced diagnostic technologies, the global veterinary molecular diagnostics market is poised for sustained expansion, driven by a dynamic interplay of technological innovation, evolving healthcare practices, and increasing awareness of animal and public health.

Select Competitors (Total 42 Featured) -

• BIOMEDICA Medizinprodukte GmbH & Co., KG
• Bioneer Corporation
• HealthGene Corporation
• Idexx Laboratories, Inc.
• Novacyt Group
• Qiagen NV
• Thermo Fisher Scientific, Inc.
• Vca, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.